Cancer Therapy With Tetrathiomolybdate: Antiangiogenesis by Lowering Body Copper—A Review

A new anticopper drug, tetrathiomolybdate (TM), developed for Wilson’s disease, is a very promising antiangiogenic agent. Copper levels lowered into an antiangiogenic window by TM have shown efficacy against cancer in a variety of animal models as well as in patients. The only significant toxicity so far results from over treatment and excessive bone marrow depletion of copper. The resulting anemia and/or leukopenia is easily treatable by dose reduction or drug holiday. The underlying concept for TM efficacy as an anticancer agent is that when the body’s copper status is in the window, cellular copper needs are met and toxicity is avoided. Copper status is relatively easily monitored by following serum ceruloplasmin, a copper-containing protein secreted by the liver at a rate dependent upon the amount of copper in the liver available to incorporate into the protein. The authors speculate that the copper level is a primitive angiogenesis and growth-signaling regulator that has been retained throughout evolution.

• Publication year

  2002

• Venue

  Integrative Cancer Therapies

• Publication date

  2002-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1177/1534735402238185PMID 14664727
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An Anticopper Antiangiogenic Approach for Advanced Cancer in Spontaneously Occurring Tumors Using Tetrathiomolybdate: A Pilot Study in a Canine Animal Model

  2004cited by this paper
• An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action

  2004cited by this paper
• Radiotherapy and antiangiogenic TM in lung cancer.

  2002cited by this paper
• Prediction: Pig Organ Transplants to Humans Within 5 Years

  2002cited by this paper
• The Role of Copper Suppression as an Antiangiogenic Strategy in Head and Neck Squamous Cell Carcinoma

  2001cited by this paper
• Wilson’s Disease: A Clinician’s Guide to Recognition, Diagnosis, and Management

  2001cited by this paper
• Consensus Panel: Antiangiogenesis Drugs Unlikely as Single Agents

  2001cited by this paper
• Copper Induces the Assembly of a Multiprotein Aggregate Implicated in the Release of Fibroblast Growth Factor 1 in Response to Stress*

  2001cited by this paper
• Copper Control as an Antiangiogenic Anticancer Therapy: Lessons from Treating Wilson's Disease

  2001cited by this paper
• Recognition, Diagnosis, and Management of Wilson's Disease (44460)

  2000cited by this paper
• WILSON'S DISEASE.

  2000cited by this paper
• Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study.

  2000cited by this paper
• Treatment of Wilson's disease with zinc. XVII: Treatment during pregnancy

  2000cited by this paper
• The content of different copper compounds in the gray forest soils of Mordovia and the effectiveness of the treatment of barley seeds with copper sulfate before planting

  2000cited by this paper
• Mineral composition of pastures in the North and Northwest regions of Rio de Janeiro State: 2. Manganese, iron, zinc, copper, cobalt, molybdenum and lead

  2000cited by this paper
• Copper-regulatory domain involved in gene expression.

  1999cited by this paper
• Deficiências e desequilíbrios minerais em bovinos e ovinos ¾ revisão dos estudos realizados no Brasil de 1987 a 1998

  1999cited by this paper
• Factors promoting tumor angiogenesis.

  1999cited by this paper
• Angiogenesis and Cancer Control: From Concept to Therapeutic Trial.

  1999influential reference
• Copper transport and its disorders : molecular and cellular aspects

  1999cited by this paper
• Treatment of Wilson's disease with zinc: XV long-term follow-up studies.

  1998cited by this paper
• Growth factor release from amylopectin hydrogel based on copper coordination.

  1998cited by this paper
• GRISEA, a copper-modulated transcription factor from Podospora anserina involved in senescence and morphogenesis, is an ortholog of MAC1 in Saccharomyces cerevisiae

  1998cited by this paper
• Interaction of human angiogenin with copper modulates angiogenin binding to endothelial cells.

  1997cited by this paper
• Mitochondrial DNA rearrangements of Podospora anserina are under the control of the nuclear gene grisea.

  1997cited by this paper
• Copper-specific Transcriptional Repression of Yeast Genes Encoding Critical Components in the Copper Transport Pathway*

  1997cited by this paper
• Homeostatic Regulation of Copper Uptake in Yeast via Direct Binding of MAC1 Protein to Upstream Regulatory Sequences ofFRE1 and CTR1 *

  1997cited by this paper
• Evidence for the Saccharomyces cerevisiae Ferrireductase System Being a Multicomponent Electron Transport Chain*

  1996cited by this paper
• Histopathology of enzootic ataxia in Sika deer (Cervus nippon Temminck).

  1996cited by this paper
• Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy.

  1996influential reference
• Treatment of Wilson Disease With Ammonium Tetrathiomolybdate: III. Initial Therapy in a Total of 55 Neurologically Affected Patients and Follow-up With Zinc Therapy

  1996cited by this paper
• GRISEA, a putative copper-activated transcription factor fromPodospora anserina involved in differentiation and senescence

  1996cited by this paper
• Evidence for Cu(II) Reduction as a Component of Copper Uptake by Saccharomyces cerevisiae(*)

  1995cited by this paper
• Angiogenesis in cancer, vascular, rheumatoid and other disease

  1995cited by this paper
• Angiogenesis and breast cancer.

  1994cited by this paper
• SPARC is a source of copper-binding peptides that stimulate angiogenesis

  1994cited by this paper
• The Saccharomyces cerevisiae copper transport protein (Ctr1p). Biochemical characterization, regulation by copper, and physiologic role in copper uptake.

  1994cited by this paper
• Treatment of Wilson's disease with zinc. XIII: Therapy with zinc in presymptomatic patients from the time of diagnosis.

  1994cited by this paper
• Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients.

  1994cited by this paper
• Metal concentrations in chrionomids in relation to peatland geochemistry

  1994cited by this paper
• Treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction.

  1992cited by this paper
• Inactivation of human fibroblast growth factor-1 (FGF-1) activity by interaction with copper ions involves FGF-1 dimer formation induced by copper-catalyzed oxidation.

  1992cited by this paper
• Wilson Disease

  1992cited by this paper
• Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.

  1992cited by this paper
• Initial therapy of patients with Wilson's disease with tetrathiomolybdate.

  1991cited by this paper
• Anticopper treatment inhibits pseudopodial protrusion and the invasive spread of 9L gliosarcoma cells in the rat brain.

  1990cited by this paper
• Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor.

  1990cited by this paper
• Human vascular permeability factor. Isolation from U937 cells.

  1989cited by this paper
• Characterization and quantification of copper sulfate-induced vascularization of the rabbit cornea.

  1988cited by this paper
• Purified monocyte‐derived angiogenic substance (angiotropin) stimulates migration, phenotypic changes, and “tube formation” but not proliferation of capillary endothelial cells in vitro

  1987cited by this paper
• Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy.

  1987cited by this paper
• Management of Wilson's disease with zinc sulphate. Experience in a series of 27 patients.

  1987cited by this paper
• Angiogenic factors.

  1987cited by this paper
• How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture.

  1986cited by this paper
• Copper and zinc absorption in the rat: mechanism of mutual antagonism.

  1985cited by this paper
• Copper metabolism in rats given di- or trithiomolybdates.

  1982cited by this paper
• Role of prostaglandin E1 and copper in angiogenesis.

  1982cited by this paper
• Cancer : Principles and Practice of Oncology

  1982cited by this paper
• Ceruloplasmin, copper ions, and angiogenesis.

  1982cited by this paper
• Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride.

  1982cited by this paper
• Effects of molybdate, sulfide, and tetrathiomolybdate on copper metabolism in rats.

  1981cited by this paper
• An investigation of the effects of intravenous administration of thiomolybdate on copper metabolism in chronic Cu-poisoned sheep

  1981cited by this paper
• Wilson's disease.

  1981cited by this paper
• Regulation of intestinal metallothionein biosynthesis in rats by dietary zinc.

  1981cited by this paper
• Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate.

  1981cited by this paper
• Oral zinc sulphate as long-term treatment in Wilson's disease (hepatolenticular degeneration).

  1979cited by this paper
• Copper regulation of ceruloplasmin in copper-deficient rats.

  1979cited by this paper
• Intestinal metallothionein and the mutual antagonism between copper and zinc in the rat.

  1979cited by this paper
• Hypocupremia induced by zinc therapy in adults.

  1978cited by this paper
• Major Problems in Internal Medicine

  1978cited by this paper
• Trace element metabolism in man and animals, 3 : proceedings of the 3rd international symposium, Freising, Fed. Rep. of German, July 77

  1978cited by this paper
• Oral zinc in Wilson's disease.

  1978cited by this paper
• Zinc metabolism : current aspects in health and disease : Proceedings of Symposium Sponsored by Meyer Laboratories Institute Research Fort Lauderdale, Florida, November 11-12, 1976

  1977cited by this paper
• The use of pharmacological doses of zinc in the treatment of sickle cell anemia.

  1977cited by this paper
• Thiomolybdates and the copper–molybdenum–sulphur interaction in ruminant nutrition

  1975cited by this paper
• Anti‐Angiogenesis: New Concept for Therapy of Solid Tumors

  1972cited by this paper
• Tumor angiogenesis: therapeutic implications.

  1971cited by this paper
• Effect of dietary molybdenum and sulfate upon copper metabolism in sheep.

  1969cited by this paper
• Copper concentration and cytochrome-oxidase and ribonuclease activities in the brains of copper-deficient lambs.

  1962cited by this paper
• Influence of excess dietary molybdenum on rat and calf liver and heart enzymes.

  1960cited by this paper
• Interrelations of copper, molybdenum and sulfate sulfur in nutrition.

  1960cited by this paper
• Interrelations of copper, molybdenum and sulfate sulfur in nutrition.

  1960cited by this paper
• Metabolic effects of molybdenum toxicity in the rat.

  1958cited by this paper
• Penicillamine, a new oral therapy for Wilson's disease.

  1956cited by this paper
• Some preliminary observations on the effect of molybdenum on copper metabolism in herbivorous animals.

  1945cited by this paper
• The teart pastures of Somerset: I. The cause and cure of teartness

  1943cited by this paper
• A NATURAL COPPER DEFICIENCY IN CATTLE RATIONS.

  1931cited by this paper

• Targeting cuproptosis in liver cancer: Molecular mechanisms and therapeutic implications

  2025cites this paper
• Metabolic Disorders in Mice Bearing Transplantable Hepatoma 22a: a Focus on Ceruloplasmin

  2025cites this paper
• Targeting mineral metabolism in cancer: Insights into signaling pathways and therapeutic strategies.

  2025cites this paper
• Mitochondrial Sulfenated-Protein-Targeted Covalent Immobilization Boosting Efficient Copper(II) Depletion for Enhanced Cancer Treatment.

  2024cites this paper
• The Antitumor Impact of Combining Hepatic Artery Ligation With Copper Chelators for Liver Cancer

  2023cites this paper
• Modulation of Intracellular Copper Levels as the Mechanism of Action of Anticancer Copper Complexes: Clinical Relevance

  2021influential citation
• Copper depletion modulates mitochondrial oxidative phosphorylation to impair triple negative breast cancer metastasis

  2021cites this paper
• Multitargeting Strategy Using Tetrathiomolybdate and Lenvatinib: Maximizing Anti-angiogenesis Activity in a Preclinical Liver Cancer Model.

  2021cites this paper
• Interference between copper transport systems and platinum drugs.

  2021cites this paper
• Ammonium tetrathiomolybdate treatment of copper‐associated hepatopathy in dogs

  2019influential citation
• Copper chaperone ATOX1 is required for MAPK signaling and growth in BRAF mutation-positive melanoma.

  2019cites this paper
• Developing Ligands to Target Transition Metals in Cancer

  2019cites this paper
• Effects of Copper Chelation on BRAFV600E Positive Colon Carcinoma Cells

  2019cites this paper
• Primary breast cancer in a patient with Wilson disease

  2019cites this paper
• Platinum drugs, copper transporters and copper chelators

  2018cites this paper
• Canine Copper-Associated Hepatitis.

  2017cites this paper
• Copper suppression as cancer therapy: the rationale for copper chelating agents in BRAFV600 mutated melanoma.

  2016cites this paper
• The promise of copper lowering therapy with tetrathiomolybdate in the cure of cancer and in the treatment of inflammatory disease.

  2014cites this paper
• SYNTHESIS AND CHARACTERISATION OF MIXED METAL COMPLEXES OF Fe-W WITH SCHIFF BASES OF TRIETHYLENE TETRAMINE

  2014cites this paper
• Long-Term Remission of Adenoid Cystic Tongue Carcinoma with Low Dose Naltrexone and Vitamin D 3 – A Case Report

  2014cites this paper
• Long-term remission of adenoid cystic tongue carcinoma with low dose naltrexone and vitamin D3--a case report.

  2014cites this paper
• Copper chelators: chemical properties and bio-medical applications.

  2014cites this paper
• Using canine osteosarcoma as a model to assess efficacy of novel therapies: can old dogs teach us new tricks?

  2014cites this paper
• Non-hepatic tumors change the activity of genes encoding copper trafficking proteins in the liver

  2013cites this paper
• Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator.

  2010cites this paper
• Scientific Basis for Swedish Occupational Standards XXX

  2010cites this paper
• Stimulation of angiogenesis resulting from cooperation between macrophages and MDA-MB-231 breast cancer cells: proposed molecular mechanism and effect of tetrathiomolybdate

  2010cites this paper
• Role of copper ion in the pathogenesis of type 2 diabetes.

  2009cites this paper
• Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm.

  2009cites this paper
• Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm

  2009cites this paper
• The use of copper-lowering therapy with tetrathiomolybdate in medicine

  2009influential citation
• Trithio-chloro molybdate [MoClS3]-: a versatile precursor for molybdenum trisulfido complexes.

  2008cites this paper
• Effects of ammonium tetrathiomolybdate, an oncolytic/angiolytic drug on the viability and proliferation of endothelial and tumor cells

  2007cites this paper
• Preadministration of High-Dose Salicylates, Suppressors of NF-κB Activation, May Increase the Chemosensitivity of Many Cancers: An Example of Proapoptotic Signal Modulation Therapy

  2006cites this paper
• Combination tetrathiomolybdate and radiation therapy in a mouse model of head and neck squamous cell carcinoma.

  2006cites this paper
• S100A13, a new marker of angiogenesis in human astrocytic gliomas

  2006cites this paper
• Inhibition of in-stent restenosis by oral copper chelation in porcine coronary arteries.

  2006cites this paper
• Patients with nasopharyngeal carcinoma demonstrate enhanced serum and tissue ceruloplasmin expression.

  2006cites this paper
• Copper Binding by Tetrathiomolybdate Attenuates Angiogenesis and Tumor Cell Proliferation through the Inhibition of Superoxide Dismutase 1

  2006cites this paper
• Copper chelation with tetrathiomolybdate suppresses adjuvant-induced arthritis and inflammation-associated cachexia in rats

  2005cites this paper
• Anticopper therapy against cancer and diseases of inflammation and fibrosis.

  2005cites this paper
• Psychosocial Oncology

  2005cites this paper
• Naturopathic Approach

  2005cites this paper
• Inhibition of breast adenocarcinoma growth by intratumoral injection of lipophilic long-acting lathyrogens.

  2005cites this paper
• Efficacy of zinc supplementation in preventing acute hepatitis in Long–Evans Cinnamon rats

  2005cites this paper
• Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy

  2004cites this paper
• Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation

  2003cites this paper
• Copper lowering therapy with tetrathiomolybdate produces antiangiogenic, anticancer, antifibrotic, and antiinflammatory effects

  2003cites this paper
• Normal copper metabolism and lowering copper to subnormal levels for therapeutic purposes

  year unknowncites this paper